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The “360° GH in Europe” meeting, which examined various aspects of GH diseases, 
was held in Lisbon, Portugal, in June 2016. The Merck KGaA (Germany) funded meeting 
comprised three sessions entitled “Short Stature Diagnosis and Referral,” “Optimizing 
Patient Management,” and “Managing Transition.” Each session had three speaker pre-
sentations, followed by a discussion period, and is reported as a manuscript, authored 
by the speakers. The first session examined current processes of diagnosis and referral 
by endocrine specialists for pediatric patients with short stature. Requirements for 
referral vary widely, by country and by patient characteristics such as age. A balance 
must be made to ensure eligible patients get referred while healthcare systems are not 
over-burdened by excessive referrals. Late referral and diagnosis of non-GH deficiency 
conditions can result in increased morbidity and mortality. The consequent delays in 
making a diagnosis may compromise the effectiveness of GH treatment. Algorithms for 
growth monitoring and evaluation of skeletal disproportions can improve identification 
of non-GH deficiency conditions. Performance and validation of guidelines for diagnosis 
of GH deficiency have not been sufficiently tested. Provocative tests for investigation of 
GH deficiency remain equivocal, with insufficient information on variations due to patient 
characteristics, and cutoff values for definition differ not only by country but also by the 
assay used. When referring and diagnosing causes of short stature in pediatric patients, 
clinicians need to rely on many factors, but the most essential is clinical experience.
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iNtrODUctiON
A pediatric patient with short stature and no clinically evident reason generally requires referral to 
an endocrine specialist to identify the cause. The subsequent diagnosis may include one of several 
conditions in which GH therapy has been approved for use. Guidelines for referral vary widely, but 
should be sufficient to enable patients to receive appropriate treatment without over-burdening the 
healthcare systems. For optimal efficacy of GH treatment, the appropriate diagnosis should be made 
and treatment initiated as early as possible in the life of the patient (1). Published guidelines for diag-
nosis of conditions that require GH therapy are not universal or free from inaccuracies, varying with 
both the immunoassays used (2, 3) and clinical factors such as the age and body mass index (BMI) of 
the patient (4, 5). Cutoff values of GH provocation tests used to determine whether a patient receives 
GH treatment also vary according to country-specific regulations and socioeconomic conditions. 
While the majority of short stature cases treatable with GH involve idiopathic GH deficiency, the 
cause must be identified as specifically as possible and there are a number of non-GH deficiency 
short stature conditions that have approval in various countries and for individual GH formulations 
table 1 | Comparison of country-specific guidelines for referral of short children for diagnostic work-up.
auxological criteria Dutch guideline Finnish guideline british guideline
cutoff sensitivity (%) specificity (%) cutoff sensitivity (%) specificity (%) cutoff sensitivity (%) specificity (%)
Height SDS <−2.5 48 99.1 <−2.2 74 98.4 <−2.7 30 99.4
Height SDS–target height SDS <−1.6 70 99.1 <−2.2 61 94.4 <−2.0 39 99.0
Height deflection >1.0 SD 4 99.9 >2.2 SD 9 88.0 >1.3 SD 4 97.1
Any of the above criteria 74 98.5 78 83.7 57 95.8
Adapted from data reported by Stalman et al. (14).
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(6, 7). The following report summarizes the first of the three ses-
sions from a meeting held in Lisbon, Portugal, funded by Merck 
KGaA (Germany), which aimed to examine aspects of diagnosis 
and referral for GH treatment. The reports from the sessions on 
optimizing patient management and on transition from pediatric 
to adult care are published in accompanying articles (8, 9).
cliNical iNDicatiONs FOr reFerral 
FOr sHOrt statUre
Short stature can be due to various etiologies and the cause may 
be a primary or secondary growth disorder, or idiopathic (10). 
Primary growth disorders are intrinsic to the growth plate and 
include clinically defined syndromes, factors that result in being 
born small for gestational age (SGA), and skeletal dysplasias. 
Secondary growth disorders are believed to change the milieu of 
the growth plate and include GH deficiency, disorders of the GH–
insulin-like growth factor (IGF)-I axis including IGF-I deficiency 
or resistance, endocrine and metabolic disorders, organ system 
disorders, malnutrition, psychosocial disorders, and iatrogenic 
conditions. Patients with idiopathic short stature (ISS) have no 
discernible cause, the condition is very heterogeneous and may 
be either familial or non-familial. In all cases, an early diagnosis 
is important and, therefore, height screening programs must be 
sufficiently sensitive and specific to ensure timely detection and 
treatment (11). The prevalence of pathological cases among chil-
dren referred for short stature has been reported to range from 
1.3 to 19.8% (11), depending on the criteria for referral. There are 
no indicators to suggest that pathological causes of growth failure 
have different prevalence in different countries, except for growth 
failure caused by malnutrition, which is obviously dependent on 
socioeconomic circumstances.
After exclusion of clinical conditions that may result in short 
stature, a diagnosis of the cause of growth failure and potential 
need for GH treatment should be made by an endocrine spe-
cialist. Such patients require a referral, which may come from a 
variety of sources within the healthcare system. Guidelines for 
referral vary in different countries (12), but strict application 
of criteria may lead to unnecessary referrals that over-burden 
the healthcare system (13). A comparison of Dutch, Finnish, 
and UK guidelines, based on height standard deviation score 
(SDS), height SDS in relation to target height SDS, and height 
SDS deflection, found sensitivities of 74, 78, and 57% for the 
respective guidelines when using all three criteria (Table  1) 
(14). However, the study indicated that up to 25% of children 
with pathological growth failure may not be identified and other 
factors need to be considered, such as clinical examination and 
phenotype. There is a strong gender bias in referrals for short 
stature, with girls much less likely to be referred than boys (15, 
16) and an ethnic bias may also be present (16). In all cases, up-
to-date growth standards should be used, and wherever possible 
they should be population specific. A study of Finnish girls with 
Turner syndrome found a greatly increased sensitivity to detect 
the condition when using population-specific Finnish standards 
compared with use of WHO standards (17). Similarly, a study 
of USA children with cystic fibrosis at age 2 years found growth 
failure in 9% when using WHO standards compared with 26% 
when using USA CDC prevention standards (18).
The algorithms required for referral for diagnostic work-up in 
cases with short stature differ according to the age of the patient 
(19, 20). For patients less than 3  years old, phases of catch-up 
growth occur and repeated measurements of height SDS are 
necessary. At that age, height measurements have high variability 
and less accuracy, and the decision rules based on distance from 
target height and/or height deflection have low-predictive value; 
therefore, referral should be based on severe short stature (height 
SDS <−3) or repeated measurements (height SDS <−2.5 repeated 
within 1 year). For patients older than 3 years, in addition to height 
SDS, multiple factors should be taken into consideration, such as 
a history of being born SGA, body disproportion, dysmorphic 
features, emotional deprivation or subnormal growth velocity, 
and distance from target height. However, such algorithms are 
only diagnostic tools and clinical judgment must be used in all 
cases.
Efficacy of GH treatment is better when started at a young 
age, and diagnosis should, therefore, be made as early as pos-
sible. Diagnostic delay was retrospectively examined in a cohort 
of 21 patients with pituitary stalk interruption syndrome and 
GH deficiency (21). The median age at diagnosis was 3.6 years, 
but examination of auxological criteria, as defined by the GH 
Research Society (22), indicated a median delay in diagnosis of 
2.3 years. The most effective criterion was height SDS more than 
1.5 below target height SDS, with 90% of the patients meeting this 
criterion at median age of 1 year (21).
Similarly, a delay in diagnosis of children with celiac disease 
and associated growth failure was observed (23); the study 
found that growth monitoring could have identified children 
with abnormal growth 2–3 years prior to the diagnosis of celiac 
disease. However, no single factor provided sufficient sensitivity 
and a combination of auxological factors was required. A delay 
in diagnosis of children with Turner syndrome has also been 
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shown, and a combination of factors was also found to enable 
identification at an early age (24, 25). The age of diagnosis of 
Turner syndrome is typically older than 10  years, with 22% of 
cases diagnosed at age >12  years; using factors of height SDS 
<−2, height SDS minus target height SDS <−2, and growth rate 
could have identified approximately 80% of patients with short 
stature at age <5 years (25).
There is currently no consensus on which screening tests 
should be performed when evaluating children with short stature. 
The pathology detection rate in asymptomatic short children 
remains low. In a retrospective review of 1,373 referrals for short 
stature to a pediatric endocrine clinic, there were 235 children 
with height less than the third percentile who were normal on 
physical examination and had a normal growth velocity (>5 cm/
year) with no abnormal medical history (26). Only three of these 
children had a newly diagnosed pathology, and almost 99% had 
no evident pathology on laboratory or radiological screening and 
were considered to be normal variant short stature, implying that 
there is a very low incidence of pathology in healthy short children 
growing at a normal rate. Of the three with pathology relating to 
short stature, one had IGF-I resistance and two had celiac disease, 
and celiac disease may be the underlying cause of short stature in 
2–8% of cases, particularly when other causes are excluded.
Factors such as normal IGF-I and growth velocity >25th 
percentile reduce the likelihood of GH deficiency as the cause 
of short stature (27). Highly sensitive decision rules have been 
suggested to identify which patients require GH testing (28). 
Therefore, evaluations of such patients should be directed, based 
on medical history and careful clinical examination. Algorithms 
can be drawn up to enable identification of the causes of short 
stature based on body proportions, prenatal growth, and IGF-I 
levels (11, 29, 30). Such algorithms can be used to determine 
whether genetic testing is required to detect causes of short stature 
other than GH deficiency (29). Algorithms can also be integrated 
into electronic records for automated growth monitoring and are 
more efficient than standard monitoring, so they have become the 
preferred option in current clinical practice.
DiaGNOsis aND reFerral FOr NON-
GH DeFicieNcY DisOrDers
Height screening programs in primary healthcare are not univer-
sal, even in developed countries, which frequently results in late 
diagnosis of growth disorders. In patients with Turner syndrome, 
late diagnosis at a median age of 15 years was found to be associ-
ated with increased mortality and incidence of comorbidities 
such as congenital heart defects and ovarian dysfunction (24). 
Conversely, children born SGA are more often diagnosed early, 
resulting in a longer duration of GH treatment and consequent 
increased height gain.
In order to improve referral, collaboration between primary 
and secondary healthcare providers should be promoted for 
monitoring of growth of children. In the Netherlands, guidelines 
for referral are based on screening parameters of height SDS, 
height SDS relative to target height SDS, and height SDS deflec-
tion, but result in approximately 38% of all children requiring 
referral (13). However, these evidence-based guidelines, based 
on an algorithm for diagnosis, are considered to provide the 
best sensitivity and specificity (11, 12). The algorithm includes 
a parameter of disproportion or dysmorphic features, which can 
indicate conditions such as short-stature homeobox (SHOX) gene 
insufficiency and Noonan syndrome.
Turner syndrome occurs in about 1 in 2,000 live-born girls and 
diagnosis is based on short stature, hypogonadism, and minor 
anomalies (31). Where an X chromosome is completely or partly 
missing, the condition may be associated with other anomalies 
due to SHOX haploinsufficiency (30). Diagnosis can occur pre-
natally, in newborns with lymphedema, in small children with 
short stature, at school age when associated with delayed puberty 
or, in rare cases, precocious puberty (32), or in adolescents with 
primary amenorrhea.
Skeletal disproportions can be detected by plotting the 
extremities-to-trunk ratio against height, with a deviation >−1 
SD indicating SHOX protein deficiency. Noonan syndrome is 
an autosomal dominant inherited condition with prevalence of 
approximately 1 in 2,000 live births (33). The condition is associ-
ated with mutations in the PTPN11 gene and other genes in the 
Ras/MAP kinase signaling pathway. Patients are characterized by 
facial dysmorphology, heart defects, and short stature, although 
GH is generally normal but GH sensitivity may be reduced.
Automated screening using electronic health records helps to 
improve referrals for such patients with short stature. In Finland, 
primary care nurses are trained in anthropometry techniques 
and population-specific growth references are available (34, 35). 
Screening rules are integrated into each child’s electronic records, 
with automatic transfer of abnormal values to a pediatric endo-
crinologist. Testing of this automated growth monitoring over a 
1-year period resulted in an increase in prevalence of detection 
of growth disorders in the Finnish population from 5.9 to 13.4% 
of referred children (35). In Germany, between the years 2000 
and 2005 the CrescNet program developed at Leipzig University 
enabled a reduction in age of identification of GH deficiency and 
earlier initiation of GH treatment (36). This systematic screening 
program now includes a large number of medical practices and 
pediatric endocrinology centers, and mean age at GH start has 
continued to decrease across the country.
The WHO growth standards are still used in approximately 
125 countries, even though children in Finland were shown to 
be 0.2–0.8 SD taller. Thus, use of the WHO standards would miss 
about half of the patients with Turner syndrome (17). For screen-
ing of patients born SGA, who require monitoring for continued 
short stature, software systems using population-specific neonatal 
records are available (36–38). While laboratory evaluations for 
multiple factors such as renal function, liver function, thyroid 
hormone levels, karyotyping, and skeletal dysmorphism are 
available, laboratory testing without specific diagnostic questions 
is not cost-efficient (26). Ultimately, indiscriminate testing cannot 
replace clinical skills in evaluation of patients with short stature.
GaPs iN tHe DiaGNOsis OF sHOrt 
statUre DUe tO GH DeFicieNcY
A patient who is identified as having short stature is referred to an 
endocrine specialist for investigation of the cause. The diagnosis 
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is made from clinical and phenotype assessments with growth 
monitoring and laboratory evaluations. Among conditions with 
approval for GH therapy, the most frequently identified cause is 
GH deficiency and evaluation of GH secretory status is required. 
In cases with suspected hypopituitarism, hypothalamic–pituitary 
imaging is advisable to exclude tumors and identify ectopic and 
hypoplastic pituitary glands; targeted genetic analyses may also 
be carried out. For patients thought likely to respond to GH in 
terms of growth, treatment requires appropriate resources and 
facilities to be in place, which will differ by country and also by 
the socioeconomic environment for the particular patient situa-
tion. However, there appears to be a gender bias in GH treatment 
of children with short stature in many countries; males are much 
more likely to receive GH treatment, irrespective of the underly-
ing diagnosis of the cause of short stature (15, 39).
Guidelines for initiation of endocrine investigation and for 
ensuring that children and adolescents with GH deficiency are 
identified appropriately were published by the GH Research 
Society in 2000 (22) and, more recently, by the Pediatric 
Endocrine Society (40). However, the performance of the guide-
lines and the level of validation have never been tested, and the 
guidelines start with the presumption that other causes of short 
stature, such as hypothyroidism and chronic systemic diseases, 
have been excluded. A recent systematic survey (19) of more than 
1,500 publications with reported algorithms for growth monitor-
ing found no consensus on conditions that should be targeted. 
The study identified six conditions that had been targeted (Turner 
syndrome, celiac disease, cystic fibrosis, GH deficiency, renal 
tubular acidosis, and SGA), but standardization of detection 
tools was very low, none of the studies had internal validation, 
and external validation was often incomplete. The information 
implied that the evidence supporting growth monitoring is 
suboptimal in most countries, which results in delayed diagnosis 
of severe disorders and inappropriate referrals of children with 
normal variants of growth. Therefore, while early detection of 
underlying causes of growth disorders is warranted, there remains 
a need for identifying priority target conditions and appropriate 
detection tools.
A survey among pediatric endocrinologists around the world, 
and specifically members of the European Society of Pediatric 
Endocrinology, showed that growth monitoring was very variable 
and laboratory investigations for diagnostic work-up were fre-
quently not applied in routine clinical practice (12). Laboratory 
determinations to identify cases of GH deficiency include GH 
stimulation tests, but these need to be carried out appropriately. In 
a study designed to characterize possible causes of false-positive 
diagnoses of GH deficiency, the effects of calorie intake were 
examined (41). Insulin or arginine stimulation tests were carried 
out before and after 3  days on a hypocaloric diet. The results 
showed that GH response was significantly increased after the 
hypocaloric diet. The strong influence of diet clearly contributes 
to poor reproducibility of stimulation tests and a high incidence 
of false positives.
In very young children, the GHRH-arginine test may not 
conclusively differentiate GH deficiency from normal (42) and 
the insulin tolerance test may result in hypoglycemia due to high 
sensitivity to insulin (43). Accuracy of the glucagon test was 
examined in a study of children younger than 6 years who had 
GH deficiency confirmed by peak GH less than 10 µg/l in insulin 
and arginine tests (44). The mean GH response to glucagon was 
significantly greater than both the insulin and arginine tests, 
indicating confusing diagnostic information depending on which 
of the current stimulation tests is used. The peak GH response 
to glucagon was correlated inversely with age of the patient, 
although not with BMI. However, other studies have shown that 
BMI significantly affects response to GH stimulation tests, with 
reduced peak GH seen in obese children (5). Therefore, norma-
tive data for each stimulation test according to age, sex, and BMI 
are required.
To define GH deficiency, a cutoff for peak stimulated GH 
concentration below 10  µg/l was often used, as suggested by 
the GH Research Society (22). However, cutoff values of 3 or 
5 µg/l are also used and the cutoff remains somewhat arbitrary 
(40, 45). In addition, the cutoff values for commercially available 
immunoassay-based GH stimulation tests have been shown to 
vary greatly, with little reference data available (2). A survey of 19 
health centers in Germany found little agreement between results 
(46) and an audit of current practices in Europe suggested that 
cutoffs were based on tradition rather than assay characteristics 
(47). In another study, cutoffs of 4.3–7.8 µg/l were found for dif-
ferent assays, against a value of 7.1 µg/l for an automated system 
validated against isotope-dilution mass spectrometry (3). Thus, 
clinicians should ensure that they are familiar with the assay 
being used in their local laboratory and should be aware of the 
impact of factors such as age, nutritional status, BMI, sex, and 
pubertal stage.
As well as biochemical tests, magnetic resonance imaging 
(MRI) of the central nervous system is often used to classify 
patients with GH deficiency. In a large observational study of 
patients receiving GH treatment, there were 1,844 with a diagno-
sis of either ISS or born SGA (48). Pituitary abnormalities were 
found on MRI in 151 of these patients, with pituitary hypoplasia 
observed most frequently. Ectopic posterior pituitary was found 
in 20 of the patients, which were equally distributed between 
the diagnoses of ISS and SGA. This result suggested that there 
was misclassification of patients based on the GH response to 
stimulation testing. In a recent anecdotal case, a boy aged 8 years 
and 8 months was diagnosed with GH deficiency at age 3 years, 
based on short stature and severe hypoglycemia. An earlier MRI 
showed no bright spot of the posterior pituitary, but no further 
action was taken because no evidence of diabetes insipidus was 
found. Examination of a second MRI showed that the patient had 
anterior pituitary hypoplasia, pituitary stalk agenesis, and ectopic 
posterior pituitary at the level of median eminence, which was 
incorrectly measured as a 3-mm-thick pituitary stalk (personal 
communication). Thus, MRI pitfalls in the diagnosis of structural 
pituitary abnormalities in inexperienced hands suggest that MRI 
is a factor that should be examined very carefully when making a 
diagnosis in a patient with short stature.
DiscUssiON sessiON
Identifying the need to treat patients with GH remains chal-
lenging in a number of conditions, for instance IGF-I resistance. 
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In such cases, the clinician must first rule out GH deficiency 
and then assess the status of the IGF receptor, if considered 
necessary. Algorithms for identifying growth disorders generally 
assume normal weight, but an abnormal BMI can be used to 
assess nutritional disorders or conditions such as cystic fibrosis. 
In order to improve diagnosis of short stature in patients with 
Turner syndrome, healthcare practitioners need to be given better 
criteria for testing, and factors such as delayed puberty need to be 
taken more seriously. Clinicians also need guidelines to identify 
the need for referral for children with suspected Prader–Willi 
syndrome. An international consensus has been reported (49) 
and it was noted that in Germany there are published national 
criteria and a methylation test is always performed in suspected 
cases.
Small for gestational age is a heterogeneous condition and 
the term “children born SGA” is essentially a description and not 
strictly a diagnosis. The diagnosis of GH deficiency and pituitary 
dysfunction may be missed in a number of patients (48) and there 
is a high frequency of pituitary defects, leading to the question 
of whether MRI should be used routinely in SGA. In general, it 
would be recommended to look at the patient’s phenotype and 
characteristics in cases of suspected GH deficiency and at IGF-I 
status before performing an MRI. However, GH is often initiated 
without sufficient testing, where patients may have conditions 
such as a mid-line defect, and there are protocols to identify indi-
viduals who should have MRI assessment. Not all children born 
SGA are followed up, and only children born less than 1,500 g are 
routinely followed.
There remain defects in testing for GH deficiency and WHO 
charts are not good for diagnosis in some conditions associated 
with short stature. It was noted that currently in Australia diagno-
sis of short stature is based on auxology, with limited laboratory 
testing (50), although there are no reports at present to indicate 
whether this is cost effective. However, auxology criteria are 
applied accurately and carefully in order to avoid over-treating 
of patients. Additionally, automated electronic records are avail-
able for use in Australia (51), as well as in Finland (35) and a 
number of other countries (19). National population reference 
charts are needed, although the WHO weight charts are good for 
identifying obesity in the first 2  years of life. WHO charts are 
used in Australia for the first 2 years after birth, but CDC charts 
are used subsequently; however, reference values may vary for 
specific ethnic groups.
Evaluation of GH deficiency in the first 1–2  years of life is 
difficult, since there is a lack of reference data. Some data do exist 
using random GH tests in newborns (52); however, patients in 
Germany may receive MRI testing if indicated. Genetic testing 
may also be carried out if short stature is detected early in life. 
Since the publication of the GH Research Society guidelines 
in 2000 (22), task forces have been trying to identify the best 
parameters for early diagnosis of GH deficiency. While guidelines 
have been revised to some extent (40), evaluation during very 
early childhood has not been adequately addressed and there 
remains a need for an update on consensus guidelines based on 
recent knowledge. In Germany, neonatal length and weight data 
are available (37); target height data are also determined and 
used with electronic data to provide automatic referral for short 
stature. Improved education is needed for all clinicians in order 
to provide better referral and diagnosis. The current need is to 
address the lack of links between primary and secondary medical 
facilities, and the different specialties involved.
In summary, children with short stature require referral to 
specialist centers for diagnosis of the cause of growth failure. 
Guidelines for referral vary by country and patient characteristics, 
but must be appropriate in order that healthcare systems are not 
over-whelmed. The diagnosis and, where necessary, treatment 
with GH should be initiated as early as possible. Algorithms have 
been proposed for identification of patients that may benefits 
from GH therapy for short stature, whether due to GH deficiency 
or non-GH deficiency conditions. However, performance and 
validation of guidelines for diagnosis have not been sufficiently 
tested; biochemical tests for GH deficiency remain equivocal, with 
inadequate information on effects of patient characteristics and 
definitive cutoff values. Clinicians need to rely on many factors 
for referral and diagnosis of causes of short stature in children, 
in order to provide the correct treatment with GH. Therefore, 
evaluations should be directed, based on medical history and 
careful clinical examination.
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